Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10557-020-07037-2 http://scihub22266oqcxt.onion/10.1007/s10557-020-07037-2 32671601!7360896!32671601     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cardiovasc+Drugs+Ther 2021 ; 35 (2): 249-259 Nephropedia Template TP {{tp|p=32671601|t=2021. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective |pdf=|usr=}}{{32671601}} gab.com Text Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective JO: Cardiovasc Drugs Ther http://www.kidney.de/pget.php?&tw=1&pmid=32671601 #FOAvip Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19. Twit Text FOAVip Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective ????Cardiovasc Drugs Ther http://www.kidney.de/pget.php?&tw=1&pmid=32671601 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32671601 #FOAvip English Wikipedia <ref>{{Cite pmid|32671601}}</ref> Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective #MMPMID32671601 Talasaz AH; Kakavand H; Van Tassell B; Aghakouchakzadeh M; Sadeghipour P; Dunn S; Geraiely B Cardiovasc Drugs Ther 2021[Apr]; 35 (2): 249-259 PMID32671601show ga Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19. |*Antiviral Agents/classification/pharmacology[MESH] |*COVID-19 Drug Treatment[MESH] |*Cardiovascular Diseases/epidemiology/therapy[MESH] |COVID-19/complications/epidemiology/physiopathology[MESH] |Comorbidity[MESH] |Humans[MESH] |Prognosis[MESH] |Risk Assessment[MESH]Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective (epmc).pdf DeepDyve Pubget Overpricing